oestradiol
Phase 3Small molecule
oestradiol is one of 88 small molecule programs targeting Metastatic Prostate Cancer. It is currently in Phase 3.
2
Indications
4
Total Trials
1
Active Trials
87
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
332 competitors in Treatment
#DrugCompanyPhaseTrials
1oestradiol
UUniversity Hospital, Toulouse
Phase 3
Dexilant
TakedaPreclinical
Alfenta
Jazz PharmaceuticalsPreclinical
Niclocide
BayerPreclinical
Hivid
CConrado Roberto Hoffmann Filho
Preclinical
Valium
Akero TherapeuticsPreclinical
Lotemax
PPharmos
Preclinical
Norpramin
VValidus Pharmaceuticals
Preclinical
Barhemsys
Tibotec Pharmaceuticals, IrelandPreclinical
Intuniv
PPromius Pharma, LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Adenomyosis1 trial
Metastatic Prostate Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for oestradiol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity Hospital, Toulouse